FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency data show no evidence for charges that cardiovascular guidance killed drug development, official says at ADA meeting.
You may also be interested in...
Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.
Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.